我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Updates in Medication for Sturge-Weber Syndrome: A Mini Review

Pooja Vedmurthy, Anne M. Comi

Sturge-Weber Syndrome is a rare neurovascular disease associated with glaucoma, a port wine birthmark and most commonly, leptomeningeal vascular malformations accompanied by medically refractory epilepsy. Due to the poorer prognosis associated with extensive brain involvement and early onset of seizures, aggressive and early diagnosis and seizure treatment remains a focus. The past decade has produced a base of literature published on studies and trials for interventions to treat and manage these devastating symptoms. This mini-review focuses on a recent multi-centered study of patient reported medications for SWS and on three other recent treatment trials for SWS: the use of the mTOR pathway inhibitors Sirolimus, a trial with Epidiolex (cannabidiol), and presymptomatic treatment of SWS. An overview of treatment progress for patients with SWS, can be beneficial for clinical providers and patients to determine alternative ways of management.